Sign in →

Test ID BLOD0849 Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum

Useful For

Prenatal screening for open neural tube defect

Specimen Type

Serum


Necessary Information


In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).



Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Do not collect specimen after amniocentesis as this could affect results.

2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.

Additional Information:

1. Collect blood between 15 weeks, 0 days and 22 weeks, 6 days.

2. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same test, and both tests are performed at Mayo Clinic.


Specimen Minimum Volume

0.5 mL

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  90 days
  Ambient  7 days

Day(s) Performed

Monday through Friday

Report Available

4 to 6 days

Method Name

Two-Site Immunoenzymatic (Sandwich) Assay

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

82105

Forms

1. Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595) is required

2. If not ordering electronically, complete, print, and send a General Request (T239)

Secondary ID

113382

Reporting Name

AFP Single Marker SCRN, Maternal, S

Reference Values

NEURAL TUBE DEFECTS:

An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.

AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.

 

An interpretive report will be provided.

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
Sanford Laboratories - Fargo Additional Information:

SANFORD INTERFACE BUILD INFORMATION

Result Code Result Code Description
17111 Recalculated Maternal Serum Screen
22806 Results Summary
22807 Neural Tube Defect Risk Estimate
17134 AFP
22808 AFP MOM
17141 Interpretation
17143 Recommended Follow up
17142 Additional Comments
17112 Collection Date
17113 Birthdate
17114 Calculated Age at EDD
17115 Maternal Weight
17116 Maternal Weight
17117 Insulin Dependent Diabetes
22813 Patient Race
22814 Current Cigarette Smoking Status
17123 EDD by U/S Scan
17130 GA on Collection By Dates
17125 EDD by LMP
17131 GA on Collection by Dates
17133 GA used in Risk Estimate
17119 Number of Fetuses
22815 Number of Chorions
17120 IVF Pregnancy
22817 Prev Pregnancy W/Neural Tube Defect
22818 Patient or Father of Baby has a NTD
22819 Initial or Repeat Testing
22820 Physician Phone Number
17144 General Test Information